Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	106516-24-9
Formula :	C₂₄H₂₆ClFN₄O
M.W :	440.94
SMILES Code :	FC1=CC=C(N2C3=CC=C(Cl)C=C3C(C4CCN(CCN5CCNC5=O)CC4)=C2)C=C1
Synonyms :	Lu 23-174
MDL No. :	MFCD00867749
InChI Key :	GZKLJWGUPQBVJQ-UHFFFAOYSA-N
Pubchem ID :	60149

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H315-H319-H335-H413
Precautionary Statements:	P261-P305+P351+P338

Staphylococcus aureus	50 µM	24 hours	Evaluate the antibacterial activity of Sertindole against S. aureus, results showed Sertindole significantly inhibited bacterial growth	ACS Omega. 2023 Feb 3;8(6):5415-5425
Normal human urothelial cells	20 µM	48 hours	To evaluate the cytotoxic effect of Sertindole on normal human urothelial cells, results showed minimal cytotoxicity	Int J Mol Sci. 2023 Jul 24;24(14):11852
T24	14.79 ± 0.95 µM	48 hours	To evaluate the cytotoxic effect of Sertindole on bladder cancer cell line T24, results showed significant reduction in cell viability	Int J Mol Sci. 2023 Jul 24;24(14):11852
TCCSUP	13.43 ± 0.89 µM	48 hours	To evaluate the cytotoxic effect of Sertindole on bladder cancer cell line TCCSUP, results showed significant reduction in cell viability	Int J Mol Sci. 2023 Jul 24;24(14):11852
J82	11.43 ± 0.63 µM	48 hours	To evaluate the cytotoxic effect of Sertindole on bladder cancer cell line J82, results showed significant reduction in cell viability	Int J Mol Sci. 2023 Jul 24;24(14):11852
MDA-MB-231	4.1 µM (IC50)	48 hours	Evaluate the antiproliferative activity of Sertindole on MDA-MB-231 cells, showing an IC50 of 4.1 µM	Sci Rep. 2018 Oct 25;8(1):15753
MCF-10A	27.6 µM (IC50)	48 hours	Evaluate the toxicity of Sertindole on MCF-10A cells, showing an IC50 of 27.6 µM	Sci Rep. 2018 Oct 25;8(1):15753
SUM159	9.2 µM	48 hours	Evaluate the antiproliferative activity of Sertindole on SUM159 cells, showing an IC50 of 9.2 µM	Sci Rep. 2018 Oct 25;8(1):15753

Wistar rats	Rat brain dopamine D1, D2 and 5-HT2A receptor study model	Intraperitoneal injection	0.5 mg/kg or 2.0 mg/kg	Single dose, EEDQ administered 1 hour later	To study the in vivo occupation of D1, D2 and 5-HT2A receptors by Sertindole. Results showed that Sertindole had little or no effect on D1 and D2 receptors but occupied 5-HT2A receptors more extensively and firmly.	J Psychiatry Neurosci. 1998 May;23(3):157-62
Balb/c mice	MDA-MB-231 orthotopic model	Oral gavage	10 mg/kg	Once daily for 12 days	Evaluate the antitumor effect of Sertindole on MDA-MB-231 orthotopic model, showing a 22.7% reduction in tumor volume	Sci Rep. 2018 Oct 25;8(1):15753
Rats	Conscious rats	Subcutaneous injection	2.5 mg/kg	Single dose, recorded for 165 minutes	To evaluate the effects of Sertindole on EEG in the prefrontal cortex of conscious rats. Results showed that Sertindole increased the power spectra in the 6-14 Hz frequency band, indicating EEG synchronization.	Br J Pharmacol. 1999 Nov;128(5):1055-63
Rats	Ketamine-induced schizophrenia-like behaviors model	Oral	2.5 mg/kg	Once daily for 14 days	To investigate the effects of Sertindole on the NRG1/ErbB4 and PI3K/AKT/mTOR signaling pathways in ketamine-induced schizophrenia. Results showed that Sertindole significantly ameliorated behavioral deficits, oxidative stress, and neurotransmitter level changes, and activated the NRG1/ErbB4 and PI3K/AKT/mTOR signaling pathways.	Inflammopharmacology. 2022 Oct;30(5):1891-1907

{[proInfo.proName]}

CAS No.: 106516-24-9

{[proInfo.proName]}

CAS No.: 106516-24-9

Product Citations

Alternative Products

Product Details of Sertindole

Safety of Sertindole

Related Pathways of Sertindole

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT02374567	Dementia Depr... More >>ession Schizophrenia Psychosomatic Disorders Anxiety Disorders Less <<	Phase 3	Terminated	-	Germany ... More >> Bezirkskrankenhaus Augsburg Augsburg, Germany Krankenhaus Hedwigshöhe Berlin, Germany Hannover Medical School Hannover, Germany, 30625 Asklepios Fachklinikum Lübben Lübben, Germany Asklepios Fachklinikum Teupitz Teupitz, Germany Less <<
NCT02307396	Schizophrenia ... More >> Schizophrenia and Disorders With Psychotic Features Schizoaffective Disorders Less <<	Phase 4	Completed	-	Germany ... More >> Psychiatrische Klinik und Poliklinik fuer Psychiatrie und Psychotherapie der Technischen Universitaet Muenchen am Klinikum rechts der Isar Munich, Bavaria, Germany, 81675 Less <<
NCT01765829	Psychosis Nos/Other	Phase 3	Unknown	November 2015	Spain ... More >> Mental Health Unit Villamartín Recruiting Villamartín, Cádiz, Spain, 11650 Contact: José María Mongil San Juan, MD 0034956040209 cheman45@gmail.com Principal Investigator: José María Mongil San Juan, MD Mental Health Unit Baza Recruiting Baza, Granada, Spain, 18800 Contact: Eva Bravo Barba, MD eva.bravo.barba@gmail.com Principal Investigator: Eva Bravo Barba, MD Mental Health Unit Motril Recruiting Motril, Granada, Spain, 18600 Contact: María Luisa Barrigón Estévez, MD 0034958038849 marial.barrigon.sspa@juntadeandalucia.es Principal Investigator: María Luisa Barrigón Estévez, MD Mental Health Unit Andújar Recruiting Andújar, Jaén, Spain, 23740 Contact: Fernando Sarramea Crespo, MD, PhD 0034953021717 fernandosarramea@hotmail.com Principal Investigator: Farnando Sarramea Crespo, MD, PhD Mental Health Unit Martos Recruiting Martos, Jaén, Spain, 23600 Contact: Miguel Ortigosa Luque, MD migueortigosa@hotmail.com Principal Investigator: Miguel Ortigosa Luque, MD Mental Health Unit Miraflores Not yet recruiting Alcobendas, Madrid, Spain, 28100 Contact: María Luisa Zamarro Arraz, MD, PhD 0034916530108 zamarroluisa@yahoo.es Principal Investigator: María Luisa Zamarro Arraz, MD, PhD Hospital Infanta Sofía Not yet recruiting San Sebastian de los Reyes, Madrid, Spain, 28702 Contact: María Rosario Gutiérrez Labrador, MD rosagutierrez@psiquiatra.e.telefonica.net Principal Investigator: María Rosario Guitiérrez Labrador, MD Mental Health Unit Valle del Guadalhorce Not yet recruiting Cártama, Málaga, Spain, 29580 Contact: Daniel Gutiérrez Castillo, MD 0034951033931 dgutierrezcastillo@gmail.com Principal Investigator: Daniel Gutiérrez Castillo, MD Mental Health Unit Las Lagunas Not yet recruiting Fuengiróla, Málaga, Spain, 29650 Contact: María Isabel Osuna Carmona, MD maribelosunac@hotmail.com Principal Investigator: María Isabel Osuna Carmona, MD Fundación Argibide Not yet recruiting Pamplona, Navarra, Spain, 31007 Contact: Ignacio Mata Pastor, MD, PhD 0034948266650 nacho.mata70@gmail.com Principal Investigator: Ignacio Mata Pastor, MD, PhD Hospital El Tomillar Recruiting Dos Hermanas, Seville, Spain, 41700 Contact: Joaquín Carlos Martín Muñoz, MD, PhD 0034955016083 joaquinmartin@hotmail.com Principal Investigator: Joaquín Carlos Martín Muñoz, MD, PhD Hospital Francesc de Borja Recruiting Gandía, Valencia, Spain, 46700 Contact: María Lacruz Silvestre, MD, PhD maria.lacruz.silvestre@gmail.com Principal Investigator: María Lacruz Silvestre, MD, PhD Hospital de Basurto Not yet recruiting Bilbao, Spain, 48013 Contact: Sonia Bustamante Madariaga, MD, Phd 0034944 006137 sonia.bustamantemadariaga@osakidetza.net Principal Investigator: Sonia Bustamante Madariaga, MD, PhD Mental Health Unit Tetuán Not yet recruiting Madrid, Spain, 28003 Contact: Mariano Hernández Monsalve, MD, PhD 0034915347363 hergoico@gmail.com Contact: Ruth Berdún Pe, MD ruthberdun@yahoo.es Principal Investigator: Mariano Hernández Monsalve, MD, PhD Lafora Hospital Not yet recruiting Madrid, Spain, 28049 Contact: Juan Dios Molina Martín, MD, PhD jmolinamar@hotmail.com Principal Investigator: Juan Dios Molina Martín, MD, PhD Hospital Carlos Haya Recruiting Málaga, Spain, 29009 Contact: Fermín Mayoral Cleríes, Md, PhD fermin.mayoral.sspa@juntadeandalucia.es Principal Investigator: Fermín Mayoral Cleríes, MD, PhD Virgen del Rocío Hospital Recruiting Seville, Spain, 41013 Contact: Clara M. Rosso Fernández, MD 0034955013414 claram.rosso.sspa@juntadeandalucia.es Contact: Miguel Ruiz Veguilla, MD, PhD 0034955013414 mruizveguilla@yahoo.com Principal Investigator: Miguel Ruiz Veguilla, MD, PhD Less <<
NCT02435095	Schizophrenia	Phase 4	Recruiting	April 2019	Germany ... More >> RWTH University Hospital Aachen Recruiting Aachen, NRW, Germany, 52074 Contact: Sabrina Schaffrath saschaffrath@ukaachen.de Contact: Sarah Lammertz slammertz@ukaachen.de Alexianer Aachen GmbH Not yet recruiting Aachen, Germany, 52062 Zentrum für Neurologie und Seelische Gesundheit im Kapuziner Karree Aachen Not yet recruiting Aachen, Germany, 52062 Contact: Frank Bergmann, Dr. med. LVR Klinik Bonn Recruiting Bonn, Germany, 53111 LVR Klinik Düren Not yet recruiting Düren, Germany, 52353 Klinik und Poliklinik für Psychiatrie und Psychotherapie der Heinrich-Heine-Universität Düsseldorf Recruiting Düsseldorf, Germany, 40629 LVR Klinik Essen Not yet recruiting Essen, Germany, 45147 ViaNobis Gangelt Recruiting Gangelt, Germany, 52538 Klinik Königshof (Abteilung für Allgemeine Psychiatrie) Recruiting Krefeld, Germany, 47807 LVR Klinik Langenfeld Recruiting Langenfeld, Germany, 40764 LVR Klinik Viersen Not yet recruiting Viersen, Germany, 41749 Less <<
NCT00629252	Schizophrenia	Not Applicable	Terminated(Not enough subjects... More >> have been recruited in the expected period.) Less <<	-	Switzerland ... More >> University Hospital of Psychiatry, Department Neuropsychopharmacology and Brain Imaging Zurich, ZH, Switzerland, CH-8032 Less <<
NCT00612079	Healthy	Not Applicable	Completed	-	Switzerland ... More >> University of Psychiatry Hospital Zurich, ZH, Switzerland, CH-8032 Less <<
NCT00759460	Schizophrenia	Phase 3	Completed	-	China ... More >> CN002 Beijing, China, 100083 Less <<
NCT00759421	Schizophrenia	Phase 3	Completed	-	Taiwan ... More >> TWN001 Tapei, Taiwan, 112 Less <<
NCT00654706	Schizophrenia ... More >> Cognition Less <<	Phase 3	Completed	-	United States, California ... More >> US017 Garden Grove, California, United States, 92845 US008 National City, California, United States, 91950 US001 Pasadena, California, United States, 91107 US006 Pico Rivera, California, United States, 90660 US011 San Diego, California, United States, 92126 US014 Stanford, California, United States, 94305 US026 Torrance, California, United States, 90502 United States, Colorado US016 Aurora, Colorado, United States, 80045 United States, Florida US015 Orange City, Florida, United States, 32763 US010 Tampa, Florida, United States, 33613 United States, Georgia US007 Atlanta, Georgia, United States, 30308 United States, Illinois US024 Chicago, Illinois, United States, 60640 US002 Joliet, Illinois, United States, 60435 United States, Maryland US012 Baltimore, Maryland, United States, 21204 US027 Glen Burnie, Maryland, United States, 21061 United States, New Hampshire US019 Lebanon, New Hampshire, United States, 03756 United States, New Jersey US021 Clementon, New Jersey, United States, 08021 United States, New York US013 Brooklyn, New York, United States, 11203 US025 Staten Island, New York, United States, 10305 United States, North Carolina US005 Charlotte, North Carolina, United States, 28211 US018 Durham, North Carolina, United States, 27705 United States, Pennsylvania US022 Philadelphia, Pennsylvania, United States, 19139 United States, Texas US023 Austin, Texas, United States, 78754 US020 Dallas, Texas, United States, 75235 US004 Desoto, Texas, United States, 75115 US028 Houston, Texas, United States, 77008 Less <<
NCT00885690	Schizophrenia	Not Applicable	Terminated(Due to recruitment ... More >>problems) Less <<	-	Denmark ... More >> Aalborg Psychiatric Hospital Aalborg, Denmark, 9000 Sweden Universitets Allmänna Sjukhuset, Malmø UMAS Malmø, Sweden Less <<
NCT00345982	Schizophrenia	Not Applicable	Completed	-	Denmark ... More >> Aalborg Psychiatric Hospital Aalborg, Denmark, 9000 Less <<
NCT00763438	Schizophrenia	PHASE4	COMPLETED	2025-10-10	FR002, Allonnes, 72703, France
NCT00856583	Schizophrenia	Phase 3	Completed	-	-
NCT02021201	Schizophrenia	Phase 4	Terminated(No suitable patient... More >>s could be recruited in the available time period) Less <<	-	Denmark ... More >> Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Center Glostrup Glostrup, Denmark, DK-2600 Less <<
NCT00480844	Schizophrenia	Phase 4	Unknown	-	Israel ... More >> Department of Psychiatry of the Sheba Medical Center Recruiting Ramat Gan, Tel Hashomer, Israel, 52621 Contact: Mark Weiser, Dr 03-5303773 mweiser@netvision.net.il Principal Investigator: Mark Weiser, Dr Beer-Yaakov Mental Health Center Not yet recruiting Beer-Yaakov, Israel, 70350 Principal Investigator: Yehuda Abramowitz, Dr Kfar Shaul Mental Health Center Not yet recruiting Jerusalem, Israel, 91060 Principal Investigator: Alexander Teitelbaum, Dr Less <<
NCT00864045	Schizophrenia	Phase 3	Completed	-	China ... More >> CN001 Beijing, China, 300074 Less <<
NCT01498770	-		Completed	-	-
NCT00856583	-		Completed	-	-

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	2.27mL 0.45mL 0.23mL	11.34mL 2.27mL 1.13mL	22.68mL 4.54mL 2.27mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed